Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! - VJHemOnc Podcast | Lyssna här | Poddtoppen.se
Fler avsnitt av Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance
2025-03-24 |
16 min
+
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!
2025-03-14 |
27 min
+
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes
2025-02-27 |
18 min
+
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
2025-02-21 |
13 min
+
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia
2025-02-14 |
18 min
+
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
2025-02-06 |
18 min
+
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML
2025-01-31 |
29 min
+
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
2025-01-28 |
22 min
+
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
2025-01-24 |
31 min
+
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
2025-01-17 |
19 min
+
Podden och tillhörande omslagsbild på den här sidan tillhör
VJHemOnc. Innehållet i podden är skapat av VJHemOnc och inte av,
eller tillsammans med, Poddtoppen.
En ny version av sidan finns tillgänglig.
Ladda om
Stäng
